Biotangents Secures £2.3m Funding for Revolutionary Dairy Farm Diagnostic Technology

Biotangents, a Scottish biotechnology company, has successfully secured a £2.3 million investment to advance its innovative diagnostic technology aimed at improving the detection of diseases in dairy cows. This funding round was led by Eos Investment Management Ltd, in partnership with British Business Investments through the Regional Angels Programme, alongside existing supporters Kelvin Capital and Scottish Enterprise. The company’s diagnostic device aims to tackle bovine mastitis, a costly and prevalent issue in the dairy farming industry. Current diagnostics often lead to presumptive treatments with antibiotics, contributing to antimicrobial resistance—a problem Biotangents’ rapid two-hour results aim to alleviate. The technology also promises environmental benefits by reducing milk wastage and unnecessary treatments. Biotangents plans to expand its application for human and environmental health, with on-farm trials scheduled in the UK and internationally next year. Eos' adviser, Nicky Deasy, will join Biotangents' board as the technology nears a full market launch, promising improved herd health and sustainability.